Skip to main content
PMC home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1981;59(3):449–458.

Development of new derivatives of primaquine by association with lysosomotropic carriers

A Trouet, P Pirson, R Steiger, M Masquelier, R Baurain, J Gillet
PMCID: PMC2396071  PMID: 6976852

Abstract

On the basis of the drug-carrier concept of chemotherapy, we entrapped primaquine in liposomes, and linked it to an amino acid (leucine), and to peptides (alanyl-leucine and alanyl-leucyl-alanyl-leucyl) as intermediate steps in the synthesis of covalent primaquine—glycoprotein conjugates that would be selectively recognized by hepatocytes.

The therapeutic activity of these compounds was tested in mice infected with sporozoites of Plasmodium berghei. Causal prophylatic cures were obtained after a single intravenous injection of primaquine—liposomes (60-70 mg of primaquine/kg of bodyweight) and lower doses (35 mg of primaquine/kg of bodyweight) of ala-leu-primaquine and ala-leu-ala-leu-primaquine.

The administration of such high doses was only possible as a result of the decreased toxicity of primaquine when entrapped in liposomes and confirms the validity of the drug-carrier concept for the treatment of malarial infections. The improved chemotherapeutic index of ala-leu-primaquine and ala-leu-ala-leu-primaquine resulted from their decreased toxicity and increased chemotherapeutic activity. These peptide derivatives are probably acting as pro-drugs of primaquine.

Full text

PDF
449

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alving C. R., Steck E. A., Chapman W. L., Jr, Waits V. B., Hendricks L. D., Swartz G. M., Jr, Hanson W. L. Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc Natl Acad Sci U S A. 1978 Jun;75(6):2959–2963. doi: 10.1073/pnas.75.6.2959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ashwell G., Morell A. G. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol. 1974;41(0):99–128. doi: 10.1002/9780470122860.ch3. [DOI] [PubMed] [Google Scholar]
  3. Black C. D., Watson G. J., Ward R. J. The use of Pentostam liposomes in the chemotherapy of experimental leishmaniasis. Trans R Soc Trop Med Hyg. 1977;71(6):550–552. doi: 10.1016/0035-9203(77)90155-9. [DOI] [PubMed] [Google Scholar]
  4. Fink E. Assessment of causal prophylactic activity in Plasmodium berghei yoelii and its value for the development of new antimalarial drugs. Bull World Health Organ. 1974;50(3-4):213–222. [PMC free article] [PubMed] [Google Scholar]
  5. Gregory K. G., Peters W. The chemotherapy of rodent malaria. IX. Causal prophylaxis. I. A method for demonstrating drug action on exo-erythrocytic stages. Ann Trop Med Parasitol. 1970 Mar;64(1):15–24. [PubMed] [Google Scholar]
  6. Juliano R. L., Stamp D. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem Biophys Res Commun. 1975 Apr 7;63(3):651–658. doi: 10.1016/s0006-291x(75)80433-5. [DOI] [PubMed] [Google Scholar]
  7. Kimelberg H. K. Differential distribution of liposome-entrapped [3H]methotrexate and labelled lipids after intravenous injection in a primate. Biochim Biophys Acta. 1976 Nov 2;448(4):531–550. doi: 10.1016/0005-2736(76)90108-5. [DOI] [PubMed] [Google Scholar]
  8. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  9. Masquelier M., Baurain R., Trouet A. Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion. J Med Chem. 1980 Nov;23(11):1166–1170. doi: 10.1021/jm00185a003. [DOI] [PubMed] [Google Scholar]
  10. New R. R., Chance M. L., Thomas S. C., Peters W. Antileishmanial activity of antimonials entrapped in liposomes. Nature. 1978 Mar 2;272(5648):55–56. doi: 10.1038/272055a0. [DOI] [PubMed] [Google Scholar]
  11. Trouet A., Baurain R., Deprez-De Campeneere D., Layton D., Masquelier M. DNA, liposomes, and proteins as carriers for antitumoral drugs. Recent Results Cancer Res. 1980;75:229–235. doi: 10.1007/978-3-642-81491-4_36. [DOI] [PubMed] [Google Scholar]
  12. Trouet A. Isolation of modified liver lysosomes. Methods Enzymol. 1974;31:323–329. doi: 10.1016/0076-6879(74)31034-8. [DOI] [PubMed] [Google Scholar]
  13. Trouet A. Perspectives in cancer research. Increased selectivity of drugs by linking to carriers. Eur J Cancer. 1978 Feb;14(2):105–111. doi: 10.1016/0014-2964(78)90167-6. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES